Our Expertise

Fred Hutchinson Cancer Research Center has long been recognized as the leader in providing effective treatment for patients who have been diagnosed with lymphoma, leukemia, and other life-threatening blood diseases. One of The Hutchinson Center's founders, Dr. E. Donnall Thomas, won the Nobel Prize in 1990 for this groundbreaking work in bone-marrow transplantation. Bone-marrow transplantation and its sister therapy, blood stem-cell transplantation, are among the greatest success stories in cancer treatment and have impacted patients worldwide by boosting survival rates from nearly zero to upwards of 85 percent for some blood cancers.
 
Over the years thousands of patients diagnosed with leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, myelodysplasia, multiple myeloma, and other malignant and non-malignant blood disorders have come to SCCA to receive the latest treatments developed by physician researchers at the Hutchinson Center. Not only has the Hutchinson Center/SCCA performed more bone-marrow transplants than any other center, the outcomes of SCCA patients are among the best in the country. The Fred Hutchinson Transplant program at SCCA was ranked first in outcomes in a four-year study by the National Marrow Donor Program (NMDP) that measured one-year survival rates of patients among 119 transplant centers in the United States.¹

In addition to receiving the best treatments and care, bone-marrow transplant patients will also benefit from SCCA’s patient and family support services as well as the only dedicated Long-Term Follow-Up (LTFU) program in the country that's designed to provide life-long support to people who have had transplants at SCCA.

¹ Final Report of Center-Specific Survival Rates in NMDP Facilitated Transplants Occurring Between January 1, 2002 through December 31, 2006. Note that the centers in this study (below) are anonymously identified and that Seattle Cancer Care Alliance is center #7205 as listed on page 9 of the report. SCCA, along with one other unidentified center, are the only two centers that ranked as “over-performing” in one-year survival rates of patients receiving a stem-cell transplant. For more information about NMDP visit www.marrow.org. SCCA is a member of the NMDP network.

10-15-2008

Final Report of Center-Specific Survival Rates in NMDP Facilitated Transplants (338kb)